ReviewDrug discovery today2013
Mechanistic systems modeling to guide drug discovery and development.
Review in Drug discovery today, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Identification and validation of a robust inflammation-related three-gene signature for the diagnosis of neonatal necrotizing enterocolitis via machine learning integration.Pediatric surgery international · 2026Article
- Integrating Model-Informed Drug Development With AI: A Synergistic Approach to Accelerating Pharmaceutical Innovation.Clinical and translational science · 2025Review
- An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions.Journal of pharmacokinetics and pharmacodynamics · 2023Article
- Expression of Cell-Adhesion Molecules inInternational journal of molecular sciences · 2023Article
- A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions.NPJ systems biology and applications · 2023Article
- A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro.In silico pharmacology · 2023Article
- Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure.Journal of pharmacokinetics and pharmacodynamics · 2022Review
- Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?Frontiers in medical technology · 2022Article
- Artificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development:: In Silico Smart Molecular Design.PET clinics · 2021Review
- Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease.Neuropharmacology · 2020Review
- Towards a widespread adoption of metabolic modeling tools in biopharmaceutical industry: a process systems biology engineering perspective.NPJ systems biology and applications · 2020Review
- Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.NPJ systems biology and applications · 2019Article
- QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models.The AAPS journal · 2017Article
- Multiscale Model of Mycobacterium tuberculosis Infection Maps Metabolite and Gene Perturbations to Granuloma Sterilization Predictions.Infection and immunity · 2016Article
- In silico methods for drug repurposing and pharmacology.Wiley interdisciplinary reviews. Systems biology and medicine · 2016Review
- Agent-Based Modeling in Systems Pharmacology.CPT: pharmacometrics & systems pharmacology · 2015Article
- A multi-scale approach to designing therapeutics for tuberculosis.Integrative biology : quantitative biosciences from nano to macro · 2015Article
- Bridging Systems Medicine and Patient Needs.CPT: pharmacometrics & systems pharmacology · 2015Review
- Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study.Journal for immunotherapy of cancer · 2015Review
- Systems biology for simulating patient physiology during the postgenomic era of medicine.CPT: pharmacometrics & systems pharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A crucial question that must be addressed in the drug development process is whether the proposed therapeutic target will yield the desired effect in the clinical population. Pharmaceutical and biotechnology companies place a large investment on research and development, long before confirmatory data are available from human trials. Basic science has greatly expanded the computable knowledge of disease processes, both through the generation of large omics data sets and a compendium of studies assessing cellular and systemic responses to physiologic and pathophysiologic stimuli. Given inherent uncertainties in drug development, mechanistic systems models can better inform target selection and the decision process for advancing compounds through preclinical and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.